Autor: |
Mancuso Roberta, Saresella Marina, Hernis Ambra, Marventano Ivana, Ricci Cristian, Agostini Simone, Rovaris Marco, Caputo Domenico, Clerici Mario |
Jazyk: |
angličtina |
Rok vydání: |
2012 |
Předmět: |
|
Zdroj: |
Journal of Translational Medicine, Vol 10, Iss 1, p 248 (2012) |
Druh dokumentu: |
article |
ISSN: |
1479-5876 |
DOI: |
10.1186/1479-5876-10-248 |
Popis: |
Abstract Background The use of natalizumab in multiple sclerosis (MS) may favour JC virus reactivation; this phenomenon is usually asymptomatic but can, albeit rarely, evolve into frank progressive multifocal leucoencephalopathy (PML). Methods JCV-specific CD8+ T lymphocytes were evaluated by flow cytometry over a 24-month period in 24 natalizumab-treated MS patients in whom JCV DNA was or was not detected in blood using quantitative real-time polymerase chain reaction; all these cases were asymptomatic. Results Perforin- and grazymes-containing VP-1-specific CD8+ T lymphocytes were reduced whereas CD107a-expressing cells were increased in JCV positive patients, suggesting an active degranulation of these cells; naïve CD8+ T lymphocytes were also decreased whereas memory cells were increased in patients in whom JCV reactivation was observed. Conclusion The presence of a CD8+ T lymphocyte-mediated effector immune response offers a greater insight into reactivation of JCV and its clinical sequelae, and may help the monitoring of patients on natalizumab therapy. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|